Successful Management of Active Tuberculosis During Allogeneic Hematopoietic Stem Cell Transplantation in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report and Literature Review
- PMID: 40352017
- PMCID: PMC12065618
- DOI: 10.7759/cureus.82026
Successful Management of Active Tuberculosis During Allogeneic Hematopoietic Stem Cell Transplantation in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report and Literature Review
Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy that often requires hematopoietic stem cell (HSC) allografting after relapse. Tuberculosis (TB) remains a significant concern in regions where it is endemic, posing a challenge in the management of these patients. A 38-year-old male with AML, who achieved complete remission after induction chemotherapy and three consolidation courses, relapsed one year later with additional chromosomal abnormalities. He received FLAG-Ida salvage chemotherapy and achieved both hematological and cytogenetic remission. During the pre-allograft check-up, an abdominal ultrasound revealed mesenteric adenopathies, and biopsy confirmed tuberculous adenitis. Given the urgency of HSC transplantation, the patient initiated anti-bacillary therapy (ERIP K4 capsules per day for three weeks) before starting his FB4 conditioning regimen. The therapy was continued during the transplant process. The patient completed six months of anti-bacillary treatment, with no TB reactivation observed at the latest follow-up. This case highlights the critical need for screening both donors and recipients for latent and active TB infection in endemic regions. Current literature supports the importance of pre-transplant TB screening and tailored management to address the complexities of TB treatment in stem cell transplantation, particularly in TB-endemic areas.
Keywords: acute myeloid leukemia (aml); hematopoietic stem cell; hsc transplantation; treatment; tuberculosis (tb).
Copyright © 2025, Ahnach et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures

Similar articles
-
A case of tuberculosis meningitis after allogeneic hematopoietic stem cell transplantation for relapsed Acute Myeloid Leukemia.Transpl Infect Dis. 2021 Apr;23(2):e13482. doi: 10.1111/tid.13482. Epub 2020 Oct 22. Transpl Infect Dis. 2021. PMID: 33012077 Free PMC article.
-
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.Medicine (Baltimore). 2015 Apr;94(15):e706. doi: 10.1097/MD.0000000000000706. Medicine (Baltimore). 2015. PMID: 25881847 Free PMC article. Clinical Trial.
-
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880. Cytotherapy. 2001. PMID: 12171713 Clinical Trial.
-
Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.Transplant Cell Ther. 2022 Nov;28(11):767.e1-767.e11. doi: 10.1016/j.jtct.2022.08.008. Epub 2022 Aug 13. Transplant Cell Ther. 2022. PMID: 35970301
-
Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature.Int J Infect Dis. 2010 Sep;14 Suppl 3:e187-91. doi: 10.1016/j.ijid.2009.08.001. Epub 2009 Oct 9. Int J Infect Dis. 2010. PMID: 19819176 Review.
References
-
- World Health Organization. Global Tuberculosis Report 2024. Geneva, Switzerland: World Health Organization; 2024. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
-
- Tuberculosis and hematological malignancies: real-world experience and key insights into drug-drug interactions. Dewan A, Singh R, Sachdeva I, et al. Clin Infect Dis. 2023;1:227–232.
Publication types
LinkOut - more resources
Full Text Sources